Partnering to Advance the Future of Dermatology and Save Lives
The current Sequential Digital Dermoscopic Imaging (SDDI) process is suboptimal. In one study, almost 40% of melanomas diagnosed in individuals at high risk corresponded to lesions that were not under dermoscopic surveillance.
These melanomas could have been detected at earlier stages if they had been monitored.
LumoScanner and LumoTrack have the potential to significantly improve the clinicians’ ability to capture malignancies at an earlier stage by capturing dermoscopic images of every lesion and detecting outlier lesions in terms of their rates of transformation.
Lumo’s offering can automatically document better than 85% of skin surface with a resolution of better than 40 microns and perform pose-independent mole-mapping. This level of resolution and automation allows may assist the dermatologists in detecting skin cancers at an earlier stage before the signatures of malignancy are ready visible.
Lumo may also be able to change the economics of Total Body Photography imaging from one that is always self-pay and available to only a few to a process that can be profitably performed under reimbursement for the many. Currently 2/3 of counties in US do not have adequate access to dermatologists. In some states the situation is worse. For example, in Arkansas, 69 out of 75 counties do not have adequate access to dermatology services. Lumo aims to democratize the TBP imaging and make it available to all at-risk individuals.
Lumo’s mission is to help dermatologists detect skin cancers at earlier stages, when they are more curable and less costly to treat.
